Development of an Oxcarbazepine Solid Dispersion Using Skimmed Milk to Improve the Solubility and Dissolution Profile
Abstract
Oxcarbazepine has low solubility and low oral bioavailability, so it’s a challenge to formulate suitable dosage form. In this present investigation, to improve the dissolution rate and solubility, skimmed milk is used as a carrier. Physical mixers were prepared using various drugs to carrier ratio and spray drying technology was used to develop solid dispersion with the carrier. Various techniques were used to characterize the solid dispersion immediately after they were made which includes differential scanning calorimetry, scanning electron microscopy, fourier transform infra-red spectroscopy, X-ray diffraction and in-vitro dissolution profiles. The differential scanning calorimetry thermograms of raw drug indicated of its anhydrous crystalline nature. In thermograms of solid dispersion, the characteristic peak was absent suggesting the change from crystalline nature to amorphous form. X-ray diffraction confirmed those results. X-ray diffraction results of raw drug showed highly intense peak characteristic of its crystalline nature where solid dispersion showed less intense, more diffused peak indicating the change in crystalline form. Fourier transforms infra-red spectroscopy studies showed there was no interaction between drug and carrier. Scanning electron microscopy support the amorphous nature of mixer. The whole formulation showed distinct enhancement in the drug release behavior and solubility. The optimum oxcarbazepine to skimmed milk ratio 1:3 enhances the in-vitro drug release by 3.5 fold and also show distinct increase in solubility. It was concluded that for improvement of solubility of poorly water soluble oxcarbazepine, skimmed milk powder as a carrier can be utilize very well.
Keywords:
Skimmed milk, Solid dispersion, Solubility, Multimedia Dissolution.DOI
https://doi.org/10.25004/IJPSDR.2019.110509References
Carrozzino D, Marchetti D, Laino D, Minna M, Verrocchio MC, Fulcheri M, Verrotti A, Bech P. Anxiety in adolescent epilepsy. A clinimetric analysis Nord J Psychiatry. 2016; 70(6):424-429.
Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009: 7(4):CD006453.
Tzitiridou M, Panou T, Ramantani G, Kambas A, Spyroglou K, Panteliadis C. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation. Epilepsy Behav. 2005;7(3):458-467.
Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs. 2001; 15(2):137-163.
Di L, Paul V, Takashi M. Bridging solubility between drug discovery and development. Drug Discov Today. 2012; 17(9-10):486-495.
Wlodarski K, Sawicki W, Paluch KJ, Tajber L, Grembecka M, Hawelek L, Wojnarowska Z, Grzybowska K, Talik E, Paluch M. The influence of amorphization methods on the apparent solubility and dissolution rate of Tadalafil. Eur. J. Pharm. Sci. 2014; 62:132–140.
Thayer AM. Finding solutions, Custom manufacturers take on drug solubility issues to help pharmaceutical firms move products through development. Chem Eng News. 2010; 8:13-18.
Miller DA, McConville JT, Yang W, Williams RO, McGinity JW. Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci. 2007; 96(2):361-376.
Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur. J. Pharm. Sci. 2005; 26:219-230.
Sugimoto M, Okagaki T, Narisawa S, Koida Y, Nakajima K. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. Int J Pharm. 1998; 160:11-19.
Dickinson E, Stainsby G. Advances in Food Emulsion and Foams. Elsevier Applied Sciences, London, 1988.
Sahin NO, Arslan H. Inclusion complex of prednisolone with skimmed milk. Part I: physicochemical characterization. 2007; 127(8);1255-1261.
Topaloğlu Y, Yener G, Gönüllü U. Inclusion of ketoprofen with skimmed milk by freeze-drying. Il Farmaco.1999; 54(10):648–652.
Agrawal AM, Mayur S, Patel AD, Raikes MS. Characterization and performance assessment of solid dispersions prepared by hot melt extrusion and spray drying process. Int. J. Pharm. 2013; 457(1):71-81.
Hadjira R, Jumah Masoud MS, Eltayeb SE, Narimane L, Jie Z, Qineng PI. Carbamazepine solubility enhancement in tandem with swellable polymer osmotic pump tablet: A promising approach for extended delivery of poorly water-soluble drugs. Asian J. Pharm. 2014; 9(3):146-154.
Wlodarski K, Tajber L, Sawicki W. Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA. Eur J Pharm Biopharm. 2016; 109:14–23.
Lu M, Xing H, Yang Z, Ding P. Dissolution enhancement of tadalafil by liquisolid technique. Pharma Dev Tech. 2016; 10(5):1-13.
Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 2005; 299(1-2):167–177.
Buchi N, Nalluri S. Vidyasagar, Maheswari KM. Effect of Excipients on Oxcarbazepine Release from Modified Release Matrix Tablets. J Appl Pharm Sci. 2012; 2(8); 150-158.
Patel TB, Soni TG, Suhagia BN. Preparation and characterization of oxcarbazepine microemulsion. Egypt Pharmaceut J. 2016; 15:173-80.
Philippsen FRZ, Falcao BR, Teixeira LM, Sausen TR. Development and validation of a dissolution method for a BCS class IV drug – tadalafil. IJAPA. 2017; 07(02):10-15.
Published
Abstract Display: 740 
PDF Downloads: 751 
